Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market By

Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Key Market Insights
 Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs
 The market is fragmented, featuring the presence of both established players and new entrants based in different geographies that claim to be capable of manufacturing highly potent products, at varying scales of operation
 In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies offering services across different scales of operation have established presence in various geographical regions
 In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to highly potent drug products
 In order to enhance the core competencies in this domain, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities
 Most of the installed, global HPAPI and cytotoxic drug manufacturing capacity belongs to established CMOs, accounting for close to 75% of the available capacity across various geographies
 Case-in-point: ADCs represent a significant growth opportunity; over 30 CMOs currently extend their services to manufacture one or multiple components of an ADC molecule

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *